Related Experiment Videos
Platelet function and myocardial injury during percutaneous coronary intervention
Nawsad Saleh1, Lars-Olof Hansson, Maria Kohut
1Department of Cardiology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden. nawsad.saleh@ks.se
Journal of Thrombosis and Thrombolysis
|July 9, 2002
Summary
The PFA-100 device cannot predict myocardial injury during percutaneous coronary intervention (PCI). However, it can effectively monitor the antiplatelet effects of aspirin (ASA) therapy in patients undergoing PCI.
Area of Science:
- Cardiology
- Hematology
- Interventional Cardiology
Background:
- Glycoprotein IIb/IIIa receptor inhibition may reduce myocardial injury during percutaneous coronary intervention (PCI).
- Activated platelets are hypothesized to increase the risk of myocardial injury during PCI.
- Guiding glycoprotein IIb/IIIa inhibitor use requires accurate assessment of platelet activation.
Purpose of the Study:
- To investigate platelet function using a bedside diagnostic system.
- To test the hypothesis that activated platelets increase myocardial injury risk during PCI.
- To determine if platelet function analysis can guide glycoprotein IIb/IIIa inhibitor administration.
Main Methods:
- 155 patients undergoing PCI were studied, including those with stable and unstable angina or myocardial infarction.
- Serum Troponin T levels were measured pre-PCI and post-PCI.
- Platelet function was analyzed using the PFA-100 device before PCI.
Main Results:
- The PFA-100 device did not differentiate between patients with or without myocardial injury during PCI.
- The PFA-100 device could distinguish between patients with and without acetylsalicylic acid (ASA) treatment.
Conclusions:
- The PFA-100 device is unsuitable for guiding glycoprotein IIb/IIIa inhibitor use in PCI.
- The PFA-100 device shows potential for monitoring the effectiveness of ASA therapy.